ES8800343A1 - Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia - Google Patents

Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia

Info

Publication number
ES8800343A1
ES8800343A1 ES554038A ES554038A ES8800343A1 ES 8800343 A1 ES8800343 A1 ES 8800343A1 ES 554038 A ES554038 A ES 554038A ES 554038 A ES554038 A ES 554038A ES 8800343 A1 ES8800343 A1 ES 8800343A1
Authority
ES
Spain
Prior art keywords
factor
nucleotide sequence
proteins
factor vii
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES554038A
Other languages
English (en)
Other versions
ES554038A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of ES554038A0 publication Critical patent/ES554038A0/es
Publication of ES8800343A1 publication Critical patent/ES8800343A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Retarders (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

METODO PARA PRODUCIR UNA PROTEINA QUE TIENE ACTIVIDAD BIOLOGICA PARA COAGULAR SANGRE. COMPRENDE: A) TRANSFECTAR UNA CELULA HOSPEDANTE DE MAMIFERO; B) HACER CRECER LA CELULA HOSPEDANTE DE MAMIFERO TRANSFECTADA EN UN MEDIO DE CULTIVO ADECUADO Y ENTRE 34 Y 40GC; C) CROMATOGRAFIAR LA SOLUCION DE CULTIVO, PARA AISLAR EL PRODUCTO PROTEINICO CODIFICADO POR LA CONSTRUCCION DE DNA Y PRODUCIDO POR LA CELULA HOSPEDANTE DEL MAMIFERO; D) HACER REACCIONAR LA PROTEINA AISLADA CON UNA ENZIMA PROTEOLITICA, PARA GENERAR UNA PROTEINA CON LA MISMA ACTIVIDAD BIOLOGICA PARA COAGULACION DE SANGRE QUE EL FACTOR VIIA. LA CELULA HOSPEDANTE DE MAMIFERO CONTIENE UNA CONSTRUCCION DE ADN QUE TIENE UNA SECUENCIA DE NUCLEOTIDOS O GEN SELECCIONADOS ENTRE FACTOR VII, FACTOR X Y PROTOMBINA Y CODIFICA UNA PROTEINA; EL MEDIO DE CULTIVO CONTIENE SALES, VITAMINAS, AMINOACIDOS MINERALES Y FACTORES DE CRECIMIENTO Y LA ENZIMA PROTEOLITICA SE SELECCIONA ENTRE FACTOR IXA, FACTOR XA, TROMBINA Y CALICREINA.
ES554038A 1985-04-17 1986-04-16 Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia Expired ES8800343A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72431185A 1985-04-17 1985-04-17
US06/810,002 US4784950A (en) 1985-04-17 1986-12-16 Expression of factor VII activity in mammalian cells

Publications (2)

Publication Number Publication Date
ES554038A0 ES554038A0 (es) 1987-11-01
ES8800343A1 true ES8800343A1 (es) 1987-11-01

Family

ID=27110961

Family Applications (1)

Application Number Title Priority Date Filing Date
ES554038A Expired ES8800343A1 (es) 1985-04-17 1986-04-16 Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia

Country Status (18)

Country Link
US (1) US4784950A (es)
EP (1) EP0200421B1 (es)
JP (4) JPH0824587B2 (es)
CN (1) CN1032142C (es)
AT (1) ATE92105T1 (es)
AU (1) AU603983B2 (es)
CA (1) CA1340512C (es)
DE (1) DE3688760T2 (es)
DK (2) DK175616B1 (es)
ES (1) ES8800343A1 (es)
FI (1) FI100055B (es)
GR (1) GR860984B (es)
HU (1) HU204556B (es)
IE (1) IE61982B1 (es)
LU (1) LU88806I2 (es)
NO (3) NO175066B (es)
NZ (1) NZ215842A (es)
PT (1) PT82408B (es)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DE3684546D1 (de) * 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
CA1281647C (en) * 1985-11-26 1991-03-19 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
IL82648A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Human protein s,a plasma protein regulator of hemostasis
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2600334B1 (fr) * 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
EP0289586A4 (en) * 1986-11-17 1990-04-10 New England Medical Ct INCREASING GAMMA CARBOXYLATION OF RECOMBINANT, VITAMIN K-DEPENDENT PROTEINS.
JPH03501921A (ja) * 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
DE4007902A1 (de) * 1990-03-13 1991-09-19 Behringwerke Ag Synthetische peptide, die sequenzen aus faktor viia enthalten und deren verwendung
ATE158816T1 (de) * 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5876985A (en) * 1991-04-25 1999-03-02 Board Of Regents, The University Of Texas System Methods and compositions for the preparation of recombinant Trichomonas vaginalis proteins and peptides
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US5965350A (en) * 1994-04-08 1999-10-12 Syntex (U.S.A.) Inc. Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
CN1127568C (zh) 1996-10-16 2003-11-12 津莫吉尼蒂克斯公司 成纤维细胞生长因子同系物
JP2001510168A (ja) 1997-07-18 2001-07-31 ノボ ノルディスク アクティーゼルスカブ ＦＶＩＩａ媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのＦＶＩＩａ又はＦＶＩＩａｉの使用
DE69838483T2 (de) 1997-10-14 2008-07-03 Darwin Molecular Corp. Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP0927764B1 (de) * 1997-12-03 2004-05-26 Boehringer Mannheim Gmbh Chimäre Serinproteasen
US6159722A (en) 1997-12-03 2000-12-12 Boehringer Mannheim Gmbh Chimeric serine proteases
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
CN1344320A (zh) 1998-09-23 2002-04-10 津莫吉尼蒂克斯公司 细胞因子受体zalphall
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2352532C (en) 1998-11-27 2014-10-14 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
EP1137773B1 (en) 1998-12-07 2008-08-13 ZymoGenetics, Inc. Growth factor homolog zvegf3
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
EP1141274B2 (en) 1999-01-07 2014-11-12 ZymoGenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
MXPA01009074A (es) 1999-03-09 2002-03-27 Zymogenetics Inc Nuevo ligando zalfa11 de citocina.
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
JP4732590B2 (ja) 1999-03-15 2011-07-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１及び近縁ペプチドのイオン交換クロマトグラフィー分離
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
DE60043944D1 (de) 1999-12-23 2010-04-15 Zymogenetics Inc Zytokin zcyt018
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
EP2258725A3 (en) 2000-06-26 2014-09-17 ZymoGenetics, L.L.C. Cytokine receptor zcytor17
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
BR0112119A (pt) 2000-06-30 2003-05-06 Zymogenetics Inc Polipeptìdeo isolado, molécula de ácido nucléico isolado, vetor, célula hospedeira recombinante, método de produzir a proteìna zcyto21, anticorpo ou fragmento de anticorpo, método de detectar a presença da expressão do gene zcyto21 em uma amostra biológica
KR100882482B1 (ko) 2000-09-13 2009-02-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 사람 응고 인자 ｖｉｉ 변이체
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
FR2814170B1 (fr) * 2000-09-18 2005-05-27 Rhodia Chimie Sa Nouveau latex a proprietes de surface modifiees par l' ajout d'un copolymere hydrosoluble a caractere amphiphile
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
HUP0301245A3 (en) * 2000-10-02 2005-12-28 Novo Nordisk Healthcare Ag Tmethod for the production of vitamin k-dependent proteins
US7615537B2 (en) * 2000-10-25 2009-11-10 Genzyme Corporation Methods for treating blood coagulation disorders
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
CA2441580A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US20040219543A1 (en) * 2001-04-02 2004-11-04 Ralph Wirtz Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
WO2002090600A2 (en) 2001-05-08 2002-11-14 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
AU2002333211B2 (en) 2001-09-27 2008-05-08 Novo Nordisk Health Care Ag Human coagulation factor VII polypeptides
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2298354B1 (en) 2001-10-10 2014-03-19 ratiopharm GmbH Remodelling and glycoconjugation of interferon-beta
SG159381A1 (en) 2001-10-10 2010-03-30 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
MXPA04003852A (es) * 2001-10-26 2005-02-17 Univ Tennessee Res Foundation Composiciones de vacuna estreptococica multivalente, y metodos para sus uso.
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ATE444363T1 (de) 2001-11-05 2009-10-15 Zymogenetics Inc Il-21-antagonisten
JP2005511601A (ja) * 2001-11-09 2005-04-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよび組織プラスミノゲン阻害剤を含む薬学的組成物
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
WO2003039589A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and alpha2 -antiplasmin polypeptides
US7078479B2 (en) 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
ATE428439T1 (de) * 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
EP2230299B1 (en) 2002-01-18 2011-12-07 ZymoGenetics, Inc. Novel cytokine ZCYTOR17 ligand
SI1576112T1 (sl) 2002-01-18 2012-10-30 Zymogenetics Inc Multimerni citokinski receptor zcitor17
EP2295455A1 (en) 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Cytokine receptor
AU2003221469A1 (en) * 2002-04-30 2003-11-17 Bayer Healthcare Llc FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
US6933136B2 (en) * 2002-09-20 2005-08-23 Novo Nordisk A/S Method for making recombinant proteins
WO2004029090A1 (en) 2002-09-25 2004-04-08 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
KR101204712B1 (ko) 2003-03-18 2012-11-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Ｇｌａ-잔기 함유 세린 프로테아제의 제조 방법
RU2005132164A (ru) * 2003-03-18 2006-06-10 Ново Нордиск Хелт Кэр Аг (Ch) Жидкие, водные фармацевтические композиции полипептидов фактора vii
AU2004221761B2 (en) * 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1624891B2 (en) * 2003-05-06 2013-04-10 Biogen Idec Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
NZ573412A (en) * 2003-06-19 2010-09-30 Maxygen Holdings Ltd Factor VII or VIIa Gla domain variants
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005044849A2 (en) * 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
JP4808157B2 (ja) 2003-08-07 2011-11-02 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９の均一な調製物
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
JP4824559B2 (ja) 2003-09-09 2011-11-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉポリペプチド
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP3594222B1 (en) 2003-12-01 2022-08-03 Novo Nordisk Health Care AG Virus filtration of liquid factor vii compositions
CA2549593C (en) 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
EP1732946B1 (en) 2004-03-08 2011-07-27 ZymoGenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
AU2005266892B2 (en) 2004-07-29 2011-03-03 Bristol-Myers Squibb Company Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
BRPI0514396A2 (pt) * 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
KR101364001B1 (ko) 2004-12-23 2014-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 관심있는 비타민 ｋ-의존성 단백질을 포함한 조성물 중의단백질 오염물질의 양의 감소
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
KR20130140221A (ko) 2005-04-13 2013-12-23 아스트라제네카 아베 감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
AR059945A1 (es) * 2005-08-09 2008-05-14 Zymogenetics Inc Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
ES2515915T3 (es) 2005-09-01 2014-10-30 Novo Nordisk Health Care Ag Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
ES2399138T3 (es) * 2006-03-16 2013-03-26 Stellaris Pharmaceuticals Aps Tratamiento local con factor VII
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
PL2007885T3 (pl) 2006-04-11 2010-12-31 Csl Behring Gmbh Sposób zwiększania odzysku peptydów terapeutycznych in vivo
NZ572373A (en) * 2006-05-15 2012-02-24 Ares Trading Sa Methods for treating rheumatoid arthritis using a taci-ig fusion molecule
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
KR101641899B1 (ko) 2006-06-14 2016-08-01 체에스엘 베링 게엠베하 혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2094301A4 (en) * 2006-11-30 2012-02-01 Taplmmune Inc TREATMENT OF POXVIRIDAE COMPRISING TAP-1 AND / OR TAP-2 AS MOLECULAR ADJUVANT
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US8754194B2 (en) * 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
US20100143326A1 (en) * 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
NZ579985A (en) * 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2574676B1 (en) 2007-12-27 2017-08-30 Baxalta GmbH Cell culture processes
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
EP2623112B1 (en) 2008-06-27 2015-03-04 Zymogenetics, Inc. Soluble hybrid Fc gamma receptors and related methods
EP2977461A1 (en) * 2008-11-12 2016-01-27 Baxalta Incorporated Method of producing serum-free insulin-free factor vii
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
FR2942231B1 (fr) 2009-02-19 2015-03-20 Lfb Biotechnologies Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US20120148557A1 (en) 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
JP5984676B2 (ja) 2009-12-18 2016-09-06 シーエスエル、リミテッド ポリペプチドを精製する方法
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
CA2802017A1 (en) 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
WO2012057527A2 (en) * 2010-10-26 2012-05-03 Hanmi Holdings Co., Ltd. Method for mass production of factor vii/viia
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9150846B2 (en) 2011-07-05 2015-10-06 Bioasis Technologies, Inc. P97-antibody conjugates and methods of use
PT2739649T (pt) 2011-08-05 2018-01-03 Bioasis Technologies Inc Fragmentos de p97 com atividade de transferência
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
SG10201606285YA (en) 2012-02-01 2016-09-29 Synthetic Genomics Inc Materials and methods for the synthesis of error-minimized nucleic acid molecules
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT2814840T (lt) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
CN104717973A (zh) 2012-10-10 2015-06-17 诺和诺德保健Ag（股份有限公司） 因子vii多肽的液体药物组合物
WO2014060401A1 (en) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
EP2906247A1 (en) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Factor vii conjugates
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
CN110478481A (zh) 2013-03-13 2019-11-22 比奥阿赛斯技术有限公司 p97片段及其应用
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
AU2013204728B2 (en) 2013-03-15 2016-09-15 Baxalta GmbH Methods for treating bleeding disorders using a platelet subpopulation
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
WO2015126729A1 (en) 2014-02-19 2015-08-27 Bioasis Technologies, Inc. P97-ids fusion proteins
CA2943890A1 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
EP3307237A1 (en) 2015-06-12 2018-04-18 Laboratoire Français du Fractionnement et des Biotechnologies Injectable composition of factor vii and fillers
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
WO2017044424A1 (en) 2015-09-08 2017-03-16 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
WO2019094521A1 (en) 2017-11-07 2019-05-16 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
BR112020012364A2 (pt) 2017-12-20 2020-11-24 Harbour Biomed (Shanghai) Co., Ltd anticorpos de ligação a ctla-4 e usos dos mesmos
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2019132765A1 (en) 2017-12-27 2019-07-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
CA3133357A1 (en) * 2019-03-27 2020-10-01 Sigilon Therapeutics, Inc. Compositions, devices and methods for factor vii therapy
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021040610A1 (en) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
EP4168034A1 (en) 2020-06-22 2023-04-26 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and combinations for use in the treatment of cancer
EP4203989A2 (en) 2020-09-03 2023-07-05 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022178090A2 (en) 2021-02-19 2022-08-25 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
WO2024042148A1 (en) 2022-08-26 2024-02-29 Stellaris Pharmaceuticals Aps Haemorrhage inhibiting compositions and methods involving the same
WO2024148328A2 (en) 2023-01-06 2024-07-11 Aptevo Research And Development Llc Bispecific pd-l1 and cd40 binding molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459288A (en) * 1981-05-11 1984-07-10 Baxter Travenol Laboratories, Inc. Therapeutic blood clotting factor compositions and their use
US4456591A (en) * 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
AU560686B2 (en) * 1982-08-04 1987-04-16 British Technology Group Limited Cloning vehicle dna h-factor ix elements

Also Published As

Publication number Publication date
HU204556B (en) 1992-01-28
LU88806I2 (fr) 1997-01-03
DK177386D0 (da) 1986-04-17
IE61982B1 (en) 1994-12-14
CN86102644A (zh) 1987-06-03
NZ215842A (en) 1988-04-29
JP2544090B2 (ja) 1996-10-16
EP0200421A3 (en) 1987-06-03
PT82408B (pt) 1988-08-17
HUT43634A (en) 1987-11-30
NO1996007I1 (no) 1996-06-26
FI861598A0 (fi) 1986-04-16
JPH0824587B2 (ja) 1996-03-13
DE3688760D1 (de) 1993-09-02
DK200401261A (da) 2004-08-20
EP0200421B1 (en) 1993-07-28
ES554038A0 (es) 1987-11-01
AU603983B2 (en) 1990-12-06
EP0200421A2 (en) 1986-11-05
JPS62283A (ja) 1987-01-06
NO175066B (no) 1994-05-16
FI100055B (fi) 1997-09-15
PT82408A (en) 1986-05-01
NO1996012I1 (no) 1996-10-21
DK175616B1 (da) 2004-12-27
ATE92105T1 (de) 1993-08-15
JPH10117787A (ja) 1998-05-12
JPH07163374A (ja) 1995-06-27
CA1340512C (en) 1999-04-27
FI861598A (fi) 1986-10-18
GR860984B (en) 1986-08-18
JP2835038B2 (ja) 1998-12-14
JP2726806B2 (ja) 1998-03-11
JPH07163375A (ja) 1995-06-27
AU5617786A (en) 1986-11-06
DK177386A (da) 1986-10-18
IE860995L (en) 1986-10-17
NO175066C (es) 1994-08-24
CN1032142C (zh) 1996-06-26
US4784950A (en) 1988-11-15
DE3688760T2 (de) 1993-10-28
NO861482L (no) 1986-10-20

Similar Documents

Publication Publication Date Title
ES8800343A1 (es) Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia
DE3786321D1 (de) Expression von protein-c.
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
DE69121391D1 (de) Methode zur ortsspezifischen änderung von rna und produktion von dadurch kodierten polypeptiden
DK0624199T3 (da) Fremgangsmåder til fremstilling af thrombin
DE69841674D1 (de) Vermischen von heterologen dns-sequenzen
NZ510356A (en) Molecules designated LDCAM
ATE415480T1 (de) B7l-1 moleküle
DK308586A (da) Dna-sekvens, der koder for et specifikt protein, rekombinantvektor, der omfatter sekvensen, og celler, der er transficerede til ekspression af proteinet
AU692988B2 (en) Superior thrombomodulin analogs for pharmaceutical use
NL960017I2 (nl) Expressie van Factor VIII-activiteit in zoogdiercellen.
ES2124694T3 (es) Clonacion de la n-metil-hidantoinasa.
EP0592685A4 (en) PLANT RESISTANT TO AT LEAST TWO VIRUSES AND ITS PREPARATION.

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20070912